Literature DB >> 24849064

Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab.

Miguel A Pérez-Valdivia, Manuel López-Mendoza, Francisco J Toro-Prieto, Virginia Cabello-Chaves, Mercedes Toro-Ramos, M Carmen Martín-Herrera, Luis Gómez-García.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24849064     DOI： 10.3265/Nefrologia.pre2014.Mar.12388

Source DB:  PubMed          Journal:  Nefrologia        ISSN： 0211-6995            Impact factor:   2.033


× No keyword cloud information.
  5 in total

Review 1.  Biological agents in gastrointestinal cancers: adverse effects and their management.

Authors:  Nivedita Arora; Arjun Gupta; Preet Paul Singh
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  Progression of diabetic nephropathy after successful pancreas transplantation alone: a case report.

Authors:  Yoonhong Kim; Dong Il Kim; Jae Ryong Shim; Tae Beom Lee; Kwang Ho Yang; Je Ho Ryu; Hyun Jung Lee; Byung Hyun Choi
Journal:  Korean J Transplant       Date:  2019-12-31

3.  Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.

Authors:  Alexander Tschulakow; Sarah Christner; Sylvie Julien; Maximilian Ludinsky; Markus van der Giet; Ulrich Schraermeyer
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

4.  Minimal change disease onset observed after bevacizumab administration.

Authors:  Ramy M Hanna; Eduardo Lopez; James Wilson; Shrinath Barathan; Arthur H Cohen
Journal:  Clin Kidney J       Date:  2015-12-28

5.  Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.

Authors:  Gebran Khneizer; Ahmad Al-Taee; Bahar Bastani
Journal:  J Nephropathol       Date:  2017-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.